Interleukin-6 signal transduction and lymphocyte function

Immunobiology

Volumn 202, Issue 2, 2000, Pages 151-167

  Horn, F ^a   Henze, C ^a   Heidrich, K ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; JANUS KINASE; STAT3 PROTEIN;

ACUTE PHASE RESPONSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVATION; IMMUNE SYSTEM; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 0033889959     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0171-2985(00)80061-3     Document Type: Article

References (109)

1. Interleukin 6 and its receptor: Ten years later
2. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion
3. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice
4. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells
5. T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor
6. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes
7. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells
8. Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium
9. Interleukin 6 is essential for in vivo development of B lineage neoplasms
10. CD40 and IgE: Synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells
11. Hydrocortisone and IL-4 induce IgE isotype switching in human B cells
12. CD40 ligand triggers interleukin-6 mediated B cell differentiation
13. IL-6 antisense oligonucleotides inhibit IgE production in IL-4 and anti-CD40-stimulated human B-lymphocytes
14. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6
15. Interleukin 6 and plasma cell neoplasias
16. Interleukin-6 inhibits apoptosis of malignant plasma cells
17. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias
18. Impaired immune and acute-phase responses in interleukin-6-deficient mice
19. Defective inflammatory response in interleukin-6-deficient mice
20. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses
21. Lethal tuberculosis in interleucin-6-deficient mutant mice
22. Interleucin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia
23. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: Correlation with inefficient neutrophilia
24. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection
25. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice
26. + T helper cell 1 development in interleukin-6-deficient mice infected with Candida albicans
27. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis
28. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein
29. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoreactive T cells
30. Interleukin-6 functions in autoimmune encephalomyelitis: A study in gene-targeted mice
31. Interleukin 6 is required for the development of collagen-induced arthritis
32. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment
33. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice (see comments)
34. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice
35. Structural design and molecular evolution of a cytokine receptor superfamily
36. IL-6-induced homodimerization of gp 130 and associated activation of a tyrosine kinase
37. IL-6 type cytokine receptor complexes: Hexamer, tetramer or both?
38. Interleukin-6 and related cytokines: Effect on the acute phase reaction
39. Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family
40. Association of transcription factor APRF and protein kinase JAK1 with the IL-6 signal transducer gp 130
41. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components
42. Critical cytoplasmic region of the interleukin 6 signal transducer gp 130 is conserved in the cytokine receptor family
43. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6
44. 2-macroglobulin gene
45. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family
46. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP
47. A member of the C/EBP family, NF-IL6β, forms a heterodimer and transcriptionally synergizes with NF-IL6
48. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level
49. The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family
50. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6
51. STATs and gene regulation
52. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3
53. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription
54. Growth hormone induction of hepatic serine protease inhibitor 2.1 transcription is mediated by a Stat5-related factor binding synergistically to two gamma-activated sites
55. Three-dimensional structure of the Stat3beta homodimer bound to DNA
56. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA
57. Structure of the amino-terminal protein interaction domain of STAT-4
58. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors
59. The signaling pathways of interleukin-6 and interferon-γ converge by the activation of different transcription factors which bind to common responsive DNA elements
60. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT
61. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin-6 signal transducer gp 130. II. Src homology SH2 domains define the specificity of STAT factor activation
62. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin-6 signal transducer gp 130. Definition of a novel phosphotyrosine motif mediating STAT1 activation
63. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality
64. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats
65. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients
66. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells
67. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells
68. Distinct tumorigenic potential of abl and raf in B cell neoplasia: Abl activates the IL-6 signaling pathway
69. Stat3 activation is required for cellular transformation by v-src
70. Stat3 activation by Src induces specific gene regulation and is required for cell transformation
71. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells
72. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro
73. Stat3 as an oncogene
74. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
75. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines
76. Association and activation of Btk and Tec tyrosine kinases by gp 130, a signal transducer of the interleukin-6 family of cytokines
77. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin-6-induced neuroendocrine differentiation of prostate cancer cells
78. The Btk subfamily of cytoplasmic tyrosine kinases: Structure, regulation and function
79. Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK
80. Transcriptional regulation of the junB promoter: Analysis of STAT-mediated signal transduction
81. Two signals are necessary for cell proliferation induced by a cytokine receptor gp 130: Involvement of STAT3 in anti-apoptosis
82. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3
83. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: Support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway
84. Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner
85. Suppressors of cytokine signaling (SOCS): Negative regulators of signal transduction
86. A new protein containing an SH2 domain that inhibits JAK kinases
87. Specific inhibition of Stat3 signal transduction by PIAS3
88. Inhibition of Stat1-mediated gene activation by PIAS1
89. Protein inhibitor of activated STAT-1 (signal transducer and activator of transcription-1) is a nuclear receptor coregulator expressed in human testis
90. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
91. Requirement of serine phosphorylation for formation of STAT-promoter complexes
92. Interleukin-6-induced serine phosphorylation of transcription factor APRF: Evidence for a role in interleukin-6 target gene induction
93. STAT3 activation by cytokines utilizing gp 130 and related transducers involves a secondary modification requiring an H7-sensitive kinase
94. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines
95. Gab1 acts as an adapter molecule linking the cytokine receptor gp 130 to ERK mitogen-activated protein kinase
96. Serine phosphorylation and negative regulation of Stat3 by JNK
97. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK)
98. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases
99. Activation of the signal transducer and transcription (STAT) signaling pathway in a primary T cell response. Critical role for IL-6
100. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice
101. Simultaneous activation of Ig and Oct-2 synthesis and reduction of surface MHC class II expression by IL-6
102. Interaction and functional interference of C/EBPbeta with octamer factors in immunoglobulin gene transcription
103. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma
104. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1
105. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia